Airsupra Rescue Inhaler Reduces Risk of Severe Asthma Exacerbations
AstraZeneca’s inhaled anti-inflammatory rescue medication demonstrated significant benefit compared to albuterol in a phase IIIb trial.
Tag: AirSupra
Airsupra Rescue Inhaler Reduces Risk of Severe Asthma Exacerbations
AstraZeneca’s inhaled anti-inflammatory rescue medication demonstrated significant benefit compared to albuterol in a phase IIIb trial.
Read More
AstraZeneca Sets $35 Monthly Cap on Inhaler Costs
Starting June 1, eligible patients will pay no more than $35 per month for all AstraZeneca US inhaled respiratory medicines.
Read More
FDA-approved Anti-inflammatory Rescue Inhaler for Asthma Now Available
The inhaler contains a short-acting beta2-agonist to help relax the smooth muscles of the airways and an inhaled corticosteroid to help decrease inflammation in the lungs, treating both symptoms and inflammation.
Read More
FDA Approves Airsupra Asthma Rescue Inhaler
AstraZeneca’s Airsupra is the first FDA-approved combination of an inhaled corticosteroid and a short-acting beta-agonist for prevention of asthma exacerbations.
Read More